SGRLShree Ganesh Remedies Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Shree Ganesh Remedies Limited engages in the manufacture and sale of pharmaceutical drug intermediates for active pharmaceutical ingredient (API) and fine chemicals in India and internationally. The company offers anti-arrhythmic, anti-cancer, anti-depressant, anti-diabetic, anti-diarrheal, antifungal, antihistamine, anti-inflammatory, anti-parasitic, anti-psychotic, anticholinergic, birth-control, cardiovascular, gastrointestinal, neurological disorder, ophthalmic, opioid, and veterinary API intermediates. It also provides fine and specialty chemicals, such as agro-chemicals, electronics, flavor and fragrance, life-sciences, and polymer chemicals, as well as other specialty chemicals. In addition, the company offers customized chemistry development and manufacturing; assets and infrastructure; and customized processes of pharmaceutical chemicals. It also exports its products. The company serves life sciences, flavor and fragrance, polymer industries, electronics, and agro chemicals markets. Shree Ganesh Remedies Limited was incorporated in 1995 and is headquartered in Ankleshwar, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SGRL — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 32/100)
- • Revenue growth: -41.8% YoY
- • Profit growth: -67.5% YoY
- • RSI: 41
- • MACD: bearish
Bull case
- • Debt/Equity: 0.19
- • Promoter holding: 75.9%
- • Supertrend: bullish
- • Max drawdown (1y): 15%
Bear case
- • Revenue growth: -41.8% YoY
- • Profit growth: -67.5% YoY
- • RSI: 41
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Revenue growth: -41.8% YoY
- • Profit growth: -67.5% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹38.13). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.